Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of basal cell carcinomas with methyl aminolevulinate and daylight-mediated photodynamic therapy
2010-024517-31Phase 4Completed
- Sponsor
- Hans Christian Wulf
- Start
- Feb 2011
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methyl aminolevulinate in basal cell carcinoma (BCC), sponsored by Hans Christian Wulf. Primary endpoint: Clinical treatment response at 3 months. Started Feb 2011; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2010-024517-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024517-31.